ClinicalTrials.gg
TerminatedNCT05511779Updated Dec 4, 2024

Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation

A Phase 2 interventional study of Brincidofovir in BK Virus Infection, Nephropathy and Kidney Transplantation, sponsored by SymBio Pharmaceuticals. Terminated at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by SymBio Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to delays in enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Kidney Diseases with a site in Japan — 4 open to participants now, 9 under way, 9 of them phase 3. Kidney Diseases · Japan.

Enrollment
22nd of 22
1 · median 299
Started
2022
with 3 others
Phase 2
6 of 24
none open now
Registered
19th of 24
by date

Among the 24 studies in Kidney Diseases with a site in Japan, this one is the 22nd largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2022, is one of 6 in phase 2, and was the 19th registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 184 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

4 of the 24 studies in Kidney Diseases with a site in Japan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 130 Kidney Diseases studies recruiting now, 76 (58%) set no upper age limit and 34 (26%) stop at 75 or younger; 26 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Kidney Diseases with a site in Japan, or all of them as a file.
02

Study summary

This is a Phase II, multicenter, open-label, randomized, standard of care (SOC) controlled, multiple ascending dose study to assess the safety and tolerability of IV Brincidofovir (BCV) in subjects with BKV infection after kidney transplantation. The study will be conducted at multiple study sites in several countries including Australia and Japan. Subjects who meet eligibility criteria will be enrolled in the study and will be randomized and assigned to BCV or SOC (defined as use of the same immunosuppressant administered during prescreening) before receipt of the first dose of study drug in both the Dose Escalation Phase and the Expansion Phase.

03

Conditions studied

  • BK Virus Infection
  • Nephropathy
  • Kidney Transplantation

Browse trials for

Keywords

  • BK Virus
  • Nephropathy
  • Kidney transplantation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, at least 18 years of age at the time of signing the at screening.
  • Kidney transplant recipient. "BK viral load increase and ≥ 3.6 log IU/mL" at 2 weeks post reduction or "BK viral load does not decrease by ≥ 0.3 log IU/mL" at 4 weeks post immunosuppression reduction during prescreening.

(Note: Immunosuppressant reduction needs to be continued during the screening period).

  • ≥ 30 mL/min.
  • Subjects under immunosuppression with tacrolimus, MMF/Myfortic, and/or .

Exclusion criteria

Exclusion Criteria:

  • Subjects who weigh ≥ 120 kg.
  • National Institutes of Health/ Grade 2 or higher diarrhea (ie, increase of ≥ 4 stools per day over usual pretransplant stool output) within 7 days before Day 1.
  • Poor clinical prognosis, including active or use of vasopressors other than low dose (eg, ≤ 5 μg/kg/min) dopamine for renal perfusion within 7 days before Day 1.
  • Use of renal replacement therapy within 7 days before Day 1.
  • History of intolerance to cidofovir or related compounds (ie, other nucleotide derivatives [adefovir or tenofovir])
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Dose Escalation Phase: Cohort 1: BCV 0.3 mg/kg BIW

    BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for 8 weeks (up to a maximum of 14 weeks).

    Drug: Brincidofovir

  • Experimental
    Dose Escalation Phase: Cohort 2: BCV 0.4 mg/kg BIW

    BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for 8 weeks (up to a maximum of 14 weeks).

    Drug: Brincidofovir

  • Experimental
    Expansion Phase: BCV Recommended dosage regimen in the Dose Escalation Phase

    BCV: Recommended dosage administered as a continuous IV infusion over 2 hours on Day1 and Day4 for 8 weeks (up to a maximum of 14 weeks).

    Drug: Brincidofovir

Interventions

  • BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours

    Also known as: SyB V-1901, BCV

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    * Incidence of TEAEs of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 severity and serious adverse events * Incidence of treatment-related TEAEs * Incidence of adverse events (AEs) requiring permanent discontinuation of BCV * Absolute and changes over time in safety laboratory parameters (ie, hematology, blood chemistry, and urinalysis)

    Time frame: from the time of administration of the first dose of study drug through the follow-up visit(up to 14 weeks (treatment period) and 30 days (follow-up period))

  2. Antiviral Effects

    Change from baseline in BK viral load in plasma measured through follow-up for each subject. Change from baseline in BK viral load in urine measured through follow-up for each subject. Peak BK viral load in plasma from Week 2 Day 1 through follow-up for each subject. Time-averaged area under the viremia-time curve for BK viral load in plasma from baseline through follow-up for each subject.

    Time frame: From baseline to follow-up visit(up to 14 weeks (treatment period) and 30 days (follow-up period))

07

Study locations

1 site
  • Research Site
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Apr 2023, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2022
First posted
Aug 23, 2022
StartActual
Oct 14, 2022
Primary completionActual
Apr 13, 2023
CompletionActual
Apr 13, 2023
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05511779
Responsible party
Sponsor
First posted
Aug 23, 2022
Start date
Oct 14, 2022
Primary completion
Apr 13, 2023
Completion
Apr 13, 2023
Last update
Dec 4, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brincidofovir

Start the discussion